Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tuomai Medical, has received a medical device registration certificate from the National Medical Products Administration for a polyethylene glycol embolization microsphere, marking a significant advancement in the company's interventional oncology product line [1] Group 1 - The registration certificate number is Guo Xie Zhu Ren 20263130187, valid from January 28, 2026, to January 27, 2031 [1] - The product is classified as a Class III medical device, intended for embolization treatment of hypervascular malignant tumors in solid organs [1] - This product represents the company's first embolization product in the field of tumor interventional therapy, potentially offering improved treatment options [1] Group 2 - The product must obtain a production license before it can be sold, and the sales situation remains uncertain, making it difficult to predict its impact on revenue [1]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The subsidiary involved in this development is Shanghai Tuomai Medical Technology Co., Ltd. [1]

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical has experienced fluctuations in its stock performance and financing activities, indicating a mixed market sentiment towards the company [1][2]. - On February 2, Xinmai Medical's stock fell by 2.87%, with a trading volume of 154 million yuan, and a net financing purchase of 9 million yuan, suggesting a cautious investor approach [1]. - As of February 2, the total balance of margin trading for Xinmai Medical was 482 million yuan, with a financing balance of 479 million yuan, representing 4.21% of its market capitalization, which is below the 20th percentile of the past year [1]. Group 2 - As of September 30, the number of shareholders for Xinmai Medical decreased by 8.73% to 16,000, while the average circulating shares per person increased by 9.56% to 7,708 shares [2]. - For the period from January to September 2025, Xinmai Medical reported a revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, but the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2]. - The company has distributed a total of 1.079 billion yuan in dividends since its A-share listing, with 817 million yuan distributed over the past three years [2].

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance, with revenue growth but a decline in net profit for the third quarter of 2025 [2] - As of January 29, 2026, Xinmai Medical's stock closed at 94.72 yuan, with a slight increase of 0.77% and a trading volume of 21,600 shares, resulting in a total transaction amount of 204 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 12.5 million yuan, accounting for 6.11% of the total transaction amount, while retail investors saw a net inflow of 6.98 million yuan, representing 3.41% of the total [1] Group 2 - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The third quarter of 2025 alone saw a significant revenue increase of 64.68% year-on-year, reaching 300 million yuan, although the net profit for that quarter fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85%, with investment income reported at 11.6 million yuan and a gross profit margin of 70.4% [2]

Core Viewpoint - The financial performance of Xinmai Medical (688016) shows mixed results, with revenue growth but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a total revenue of 1.015 billion yuan, an increase of 4.66% year-on-year [2]. - The net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2]. - The net profit after deducting non-recurring items fell by 25.8% to 372 million yuan [2]. - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, a substantial increase of 64.68% year-on-year [2]. - The quarterly net profit attributable to shareholders was 114 million yuan, down 23.63% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 102 million yuan, a decrease of 11.84% [2]. - The company's debt ratio stands at 15.85%, with investment income of 11.6033 million yuan and financial expenses of -7.8584 million yuan [2]. - The gross profit margin is reported at 70.4% [2]. Market Activity - As of January 28, 2026, Xinmai Medical's stock closed at 94.0 yuan, down 1.67% with a turnover rate of 1.29% and a trading volume of 15,900 hands, amounting to a transaction value of 150 million yuan [1]. - On January 28, the net outflow of main funds was 10.3432 million yuan, accounting for 6.89% of the total transaction value, while retail funds saw a net outflow of 2.9068 million yuan, making up 1.94% [1]. - Conversely, speculative funds experienced a net inflow of 13.25 million yuan, representing 8.82% of the total transaction value [1]. Analyst Ratings - In the last 90 days, seven institutions have provided ratings for Xinmai Medical, with six giving a "buy" rating and one an "increase" rating [2]. - The average target price set by institutions over the past 90 days is 1.3603 billion yuan [2].

Core Viewpoint - The article discusses the upcoming IPO of Beixin Life (科创板, 6887), highlighting its market position and financial performance in the cardiovascular intervention solutions sector. Group 1: Company Overview - Beixin Life is recognized as a leader in China's cardiovascular precision intervention solutions, focusing on clinical precision diagnosis for coronary artery diseases [2] - The company has a total market capitalization of 6.307 billion yuan and an issuance price of 17.52 yuan per share [2] - The controlling shareholder, Dr. Song Liang, has over 18 years of relevant R&D experience and the core products have received multiple certifications and awards [2] Group 2: Product and Market Position - The core product, the FFR measurement system, held a 30.6% market share in the domestic coronary indication market, ranking second with a 10.4% overall market share [2] - The product pipeline includes seven ongoing projects, with the pulse electric field ablation system currently in clinical trials [2] Group 3: Financial Performance - The company reported revenues of 318 million yuan for 2024, reflecting a 72.09% increase [3] - In the past three years, the company's revenue has shown significant growth: 184 million yuan in 2023 (+99%), and 92 million yuan in 2022 (+78.61%) [3]

Core Viewpoint - The company is a national high-tech enterprise focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform solutions for cardiovascular care [7]. Company Overview - The company specializes in the research, development, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [7]. - It is the first domestic medical device company with a combination of vascular functional FFR and imaging IVUS products, filling a market gap and changing the reliance on imported products for coronary artery disease clinical diagnosis in China [12]. Financial Data - Projected revenue for 2024 is 3.17 billion yuan, up from 1.84 billion yuan in 2023 and 0.92 billion yuan in 2022 [8]. - The company reported a net loss of 0.54 billion yuan in 2024, an improvement from a loss of 1.55 billion yuan in 2023 and 3.00 billion yuan in 2022 [8]. - Cash flow from operating activities per share is expected to be 0.08 yuan in 2024, recovering from negative cash flows in previous years [8]. Industry Context - The cardiovascular disease market is expected to grow due to an aging population, with projections indicating that by 2030, the population aged 65 and above in China will reach 270 million, accounting for 19.6% of the total population [12]. - The increasing prevalence of obesity, hypertension, and diabetes is expected to drive the demand for cardiovascular disease diagnosis and treatment solutions [12]. SWOT Analysis Strengths - The company has a strong focus on independent research and technological innovation, which is crucial for developing solutions for cardiovascular diseases [12]. - It possesses a mature commercialization network recognized globally and regionally [12]. Opportunities - The trend of population aging and increasing regulatory focus on innovative medical devices present significant growth opportunities for the company [13]. Weaknesses - The company faces challenges due to the high difficulty and risk associated with developing Class III medical devices, which involve complex and lengthy processes [14]. - There is significant competition from established foreign manufacturers, and the company has relatively weak financial strength [14].

上海微创心脉医疗科技（集团）股份有限公司于2026年1月19日召开第三届董事会第十二次会议，审议 通过使用不超过人民币100,000万元的暂时闲置募集资金进行现金管理，投资安全性高、流动性好的产 品，包括结构性存款、通知存款、定期存款、大额存单、收益凭证等，使用期限为自董事会审议通过之 日起12个月内，资金可滚动使用。该事项无需提交股东大会审议。公司承诺不影响募集资金投资计划正 常进行，所获收益将用于补足募投项目资金不足及日常经营流动资金。 截至2026年1月23日收盘，心脉医疗（688016）报收于98.1元，较上周的97.98元上涨0.12%。本周，心 脉医疗1月23日盘中最高价报98.67元。1月20日盘中最低价报95.37元。心脉医疗当前最新总市值120.92 亿元，在医疗器械板块市值排名30/127，在两市A股市值排名1779/5182。 本周关注点 公司公告汇总：心脉医疗拟使用不超过10亿元暂时闲置募集资金进行现金管理。 公司公告汇总 心脉医疗：关于使用部分暂时闲置募集资金进行现金管理的公告 中国国际金融股份有限公司关于上海微创心脉医疗科技（集团）股份有限公司使用部分暂时闲置募集资 金进行现金管理 ...